Current Programs

Q-State combines advanced human cellular models, unique measurement tools and AI machine learning into a proprietary platform that enables novel discovery of optimized genetically targeted medicines for epilepsy, pain, and other diseases of the CNS.

Disorder
Partner
Discovery
Preclinical
Clinical

Internal

Pain (antisense oligo)
Q-State - Owned
Pain (antisense oligo)
Q-State - Owned
Pain (antisense oligo dual target)
Q-State - Owned
Pain (small molecule)
Q-State - Owned
Epilepsy (antisense oligo)
Q-State - Owned
Undisclosed target 1
Q-State - Owned
Undisclosed target 2
Q-State - Owned

Partnered

Spastic Paraplegia Type 49
TECPR2 Foundation
ALS Target
QurAlis
Select Genetic Epilepsy
UCB
Undisclosed Genetic Disorder
Vertex